Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

6.400 +0.560 (+9.59%)
Official Closing Price Updated: 4:15 PM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
S&P 500 Gains 1%; US Crude Oil Inventories Increase More Than Projected
U.S. stocks traded higher midway through trading, with the S&P 500 gaining 1% on Wednesday. The Dow traded up 0.84% to 34,550.13 while the NASDAQ rose 1.32% to 13,941.87. The S&P 500, also rose,... 
Via Benzinga
Why Shares of Recursion Pharmaceuticals Are Skyrocketing Wednesday
The company just received a $50 million investment from Nvidia. 
Via The Motley Fool
Recursion Catapults 70% On Nvidia Investment For AI In Drug Development
Nvidia is hoping to help this company accelerate its efforts in AI-related drug development. 
Via Investor's Business Daily
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Nasdaq Rises Over 1%; US Inflation Rate Falls In June
U.S. stocks traded higher this morning, with the Nasdaq Composite surging over 1% on Wednesday. Following the market opening Wednesday, the Dow traded up 0.78% to 34,527.32 while the NASDAQ rose 1.18%... 
Via Benzinga
Expert Ratings for Recursion Pharmaceuticals
Via Benzinga
Recursion Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster 
From Recursion Pharmaceuticals
Via GlobeNewswire
Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider. 
Via InvestorPlace
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying
It's competing in a soon-to-be hotly contested space. 
Via The Motley Fool
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
Via Benzinga
Cathie Wood Makes Biggest Coinbase Purchase Of Year After Earnings Beat
Cathie Wood and her ARK Invest firm bought $13 million in COIN stock as they bulk up holdings following Coinbase earnings. 
Via Investor's Business Daily
$2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
$6M Bet On RxSight? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.